New combo shows promise for tough cancers
NCT ID NCT03728361
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system fight cancer) and temozolomide (a chemotherapy drug)—in people with small-cell lung cancer that has returned or stopped responding to treatment, or advanced neuroendocrine tumors. About 55 participants will receive both drugs to see if the combination can shrink tumors. The goal is to find a better option for these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center-COHORT 1
Columbus, Ohio, 43210, United States
-
Ohio State University Comprehensive Cancer Center-COHORT 2
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.